교모세포종(GBM) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Glioblastoma (GBM) Market Outlook

Thelansis's "Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Glioblastoma (GBM) Overview

Glioblastoma is the most common primary malignant brain tumor in adults, defined strictly under current WHO classification as an IDH-wildtype diffuse astrocytic glioma. It is characterized by microvascular proliferation, intense therapeutic resistance, and pseudopalisading necrosis. Driven by genomic alterations like EGFR amplification and TERT promoter mutations, its management is heavily influenced by MGMT promoter methylation status, which serves as a vital predictive biomarker for alkylating chemotherapy response rather than an oncogenic driver. Patients present with progressive headaches, seizures, and focal neurological deficits. Diagnosis relies on contrast-enhanced brain MRI showing a heterogeneously enhancing ring lesion, confirmed via histopathology. Standard frontline care utilizes maximal safe resection followed by radiotherapy and concurrent temozolomide, supplemented by tumor-treating fields. For recurrent disease, the investigational frontier focuses on combination checkpoint blockade, CAR-T platforms, dendritic cell vaccines, and oncolytic viruses within clinical trials. Median survival remains constrained at fifteen months, shifting dynamically based on age, performance status, and MGMT methylation.

Key Highlights

• In France, diagnosed GBM cases are projected to increase from 2,493 in 2025 to 2,713 by 2035.
• GBM remains the most aggressive primary malignant brain tumor in adults.
• Despite multimodal treatment, prognosis remains poor with frequent recurrence.
• Significant unmet need exists for therapies capable of improving overall survival.

Market Overview

• The Italy GBM market is projected to grow from $141.75M in 2025 to $231M by 2035.
• Market growth is driven by:
• Increased adoption of targeted and immunotherapeutic approaches
• Continued investment in novel oncology platforms
• Future growth will depend on breakthrough therapies capable of overcoming treatment resistance.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Theragnostics Ltd.
• BeyondBio Inc.
• Katmai Pharmaceuticals Inc.
• NuvOx LLC
• NeuGATE Theranostics
• Neonc Technologies, Inc.
• CNS Pharmaceuticals, Inc.
• Laminar Pharmaceuticals
• Aveta Biomics, Inc.
• Chimeric Therapeutics
• Jecho Biopharmaceuticals Co., Ltd.
• Stemline Therapeutics, Inc.
• Telix Pharmaceuticals (Innovations) Pty Limited
• Alaunos Therapeutics
• Tetragon Biosciences Ltd.
• Kintara Therapeutics, Inc.
• Orbus Therapeutics, Inc.
• CarThera
• Diakonos Oncology Corporation
• Starlight Therapeutics Inc.
• Myosin Therapeutics Inc.
• Phost'In Therapeutics
• Black Diamond Therapeutics, Inc.
• Tango Therapeutics, Inc.
• Sapience Therapeutics
• GlaxoSmithKline
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)